LONDON — An experimental cancer treatment from Roche failed to improve survival in a major lung cancer study, the company said Tuesday, a result that will further stoke doubts about the drug’s target.
In a short statement, Roche said that a combination of the drug, called tiragolumab, with its existing medicine Tecentriq did not outperform Tecentriq alone on the study’s primary endpoint of overall survival. The Phase 3 study, known as SKYSCRAPER-01, included more than 500 patients with a form of advanced non-small cell lung cancer.
Tiragolumab was designed to target a protein called TIGIT, which in recent years was seen as the next blockbuster opportunity in cancer immunotherapy. Roche and other biopharma companies poured resources into standing up anti-TIGIT programs, thinking they could augment the results of the very successful drugs that go after another protein, PD-1.
Click this link for the original source of this article.
Author: Andrew Joseph
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.
